Consistent with previous studies showing that DQS has the potential to improve immune-related disease in corneal disease by reducing the expression of Tnf-α and il-6 [20], exposure of HCECs to HS+DQS reduced the expression of several immune response cytokines (Tnf-α, il-6, il-1β, and il-1α) more than HS alone. This evidence concerns the gene IL6 and corneal disorder.